| 1.72 0.05 (2.99%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.4 | 1-year : | 2.77 |
| Resists | First : | 2.05 | Second : | 2.38 |
| Pivot price | 1.68  |
|||
| Supports | First : | 1.53 | Second : | 1.28 |
| MAs | MA(5) : | 1.65  |
MA(20) : | 1.74 |
| MA(100) : | 1.58 |
MA(250) : | 1.63 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 41.2 |
D(3) : | 25.2 |
| RSI | RSI(14): 51.3 |
|||
| 52-week | High : | 2.66 | Low : | 1.12 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CGEN ] has closed below upper band by 35.6%. Bollinger Bands are 28.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.74 - 1.75 | 1.75 - 1.76 |
| Low: | 1.63 - 1.64 | 1.64 - 1.65 |
| Close: | 1.71 - 1.72 | 1.72 - 1.73 |
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
Tue, 11 Nov 2025
Compugen Ltd. (NASDAQ:CGEN) Q3 2025 Earnings Call Transcript - Insider Monkey
Tue, 11 Nov 2025
Compugen (CGEN) Reports Q3 Loss, Lags Revenue Estimates - sharewise.com
Mon, 10 Nov 2025
CGEN: Cash runway into Q3 2027 supports advancing clinical pipeline and key partnerships - TradingView
Mon, 10 Nov 2025
Compugen: Q3 Earnings Snapshot - San Francisco Chronicle
Fri, 07 Nov 2025
Compugen Ltd expected to post a loss of 9 cents a share - Earnings Preview - TradingView
Fri, 07 Nov 2025
Compugen Ltd (CGEN) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 94 (M) |
| Shares Float | 92 (M) |
| Held by Insiders | 2 (%) |
| Held by Institutions | 16.4 (%) |
| Shares Short | 977 (K) |
| Shares Short P.Month | 944 (K) |
| EPS | -0.22 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.54 |
| Profit Margin | -87.5 % |
| Operating Margin | -670.6 % |
| Return on Assets (ttm) | -11.5 % |
| Return on Equity (ttm) | -35.7 % |
| Qtrly Rev. Growth | -81.2 % |
| Gross Profit (p.s.) | 0.14 |
| Sales Per Share | 0.23 |
| EBITDA (p.s.) | -0.21 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -7.82 |
| PEG Ratio | 0 |
| Price to Book value | 3.18 |
| Price to Sales | 7.26 |
| Price to Cash Flow | -18.58 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|